United States: A Look Inside Trump's 4-Point Plan For Curbing Drug Prices

On May 11, President Donald Trump outlined his administration's four-point plan for curbing prescription drug prices. With rare exceptions, the plan does nothing that will have immediate or even short-term effects, and missing is any reference to the presidents' campaign suggestions of direct federal price negotiation with drugmakers. Instead, the president is calling on the executive branch and, where necessary, Congress, to (1) consider (the blueprint uses the phrase "U.S. Department of Health and Human Services may"), or (2) gather more information about, the merits of taking more modest future steps that he believes will:

  • Improve competition;
  • Create a framework for better negotiation with drugmakers;
  • Provide incentives to lower the list prices of drugs; and
  • Lower patients' out-of-pocket costs.

Although the president's speech indicated that the effects would be "very soon," HHS Secretary Alex Azar more cautiously advised reporters that the changes likely would take years to accomplish. The administration has stated that most of these changes may be accomplished without legislation, but most of the ideas on which the administration is seeking more information likely would require congressional action, and others that might be implemented administratively may be challenged in court as inconsistent with existing law. The president's speech itself was short on details, but the administration released a blueprint describing action items in more detail.1

Here is a breakdown of the administration's key proposals and likely paths forward:

1. Improve Competition

In general, the administration's approach calls right now for offering modest improvements to the U.S. Food and Drug Administration approval path for generic drugs, and for the future, seeking public comment on whether easing regulatory requirements and reducing taxes that support public programs could bring about more competition.

What the Administration "May" Do

  • Expedited Generic Approvals: The FDA has already created an expedited path for approval of generic drugs where there is an off-patent brand and no generic competitor. The blueprint also indicates that the president will ask Congress to take additional steps to reduce the ability of a first-to-file generic maker to keep out other generic competitors.
  • Eliminate "Shenanigans": The administration pledges to eliminate "gaming" (the blueprint abjures Commissioner Scott Gottlieb's more colorful adjective) by drug companies that it believes stifles generic competition. It proposes that the FDA will issue guidance to address ways that drug companies may use the risk evaluation and mitigation strategy, or REMS, developed for brand drugs to delay or block competition. Specific ideas that have been mentioned in the past on this topic include (1) requiring brand makers to provide samples of their drugs to generic makers to facilitate the reverse-engineering that the generic must undertake; and (2) requiring that brand makers allow generics to use the same REMS infrastructure as the brand drug, rather than allowing the brand to restrict use to its own product.

    • Assessment: These are likely to have a pretty modest effect, since FDA approval is only one aspect of whether a generic maker would find market entry profitable. In addition, the first-to-file issue would require congressional action, and could act as a disincentive to competition, since it is currently a profitable incentive to enter the market. Acting on either of the other "shenanigans" arguably would involve property and proprietary rights that brand makers might resist in court.

What the Administration Is Seeking Ideas About

  • Price Reporting Changes: Should changes be made to the Medicaid rebate law's price reporting requirements or to other government health care program pricing reporting requirements to improve incentives and reduce barriers to price negotiation and competition?
  • Improve Commercial Markets by Reducing Government Subsidies: Should what the blueprint characterizes as increased costs imposed on industry to support government-subsidized health care (e.g., Obamacare taxes, Medicaid rebate, 340b pricing) be rolled back because they are increasing costs on commercial health plans by way of cross-subsidization?
  • More Consumer Information: What additional information from the FDA for providers and consumers would lead to greater innovation and price sensitivity in prescribing drugs?

    • Assessment: These questions are consistent with the administration's general themes that reduced regulation and taxes will improve competition, but the ideas are too unformed to lead to predictable outcomes. Changes to existing payment formulas for Medicare Part B, Medicaid rebate or 340b may require Congress to act.

2. Better Negotiation

Here, the blueprint calls for the Centers for Medicare & Medicaid Services demonstration projects that incorporate value-based care concepts, and solicits comment on a number of more significant changes that have long been part of the health policy debate, but whose prospects and effects remain uncertain.

What the Administration "May" Do

  • Center for Medicare & Medicaid Innovation Demonstrations: HHS will direct CMS to develop demonstration projects to test innovative ways to encouraged value-based care and lower prices. Mentioned are strategies to find ways to hold manufacturers accountable for outcomes, align incentives with value or volume priorities and site-neutral payments (eliminating facility payments), and provide unspecified additional "tools available to private payers outside of the Medicare program" to manage spending for high cost therapies.

    • Assessment: Although the specific negotiation tools are not made clear in the blueprint, subsequent remarks by HHS Secretary Alex Azar suggest that he believes plans might be reluctant to employ tools like fail-first and step therapy because they fear it could negatively affect their CMS star ratings. It is likely that most of these ideas could be implemented administratively, either across the board (as in the case of medication management tools) or on a trial basis, through CMMI's existing demonstration authorities.

What the Administration Is Seeking Ideas About

  • Fewer Upfront Price Concessions in Exchange for Value-Based Health Care: Should drug manufacturers be able to reduce the amounts that they pay to Medicaid (and Medicare) in rebates, and the amount of discount they provide to safety-net hospitals under the 340b program, in exchange for offering value-based health care arrangements that reward better outcomes?
  • Allowing Indication-Based Payments: Should Medicare and Medicaid be allowed to pay differently for drugs based on what conditions they are used to treat?
  • Long-Term Health Plan Financing: Should states and payers set their premium rates for periods of longer than one year to anticipate the costs of higher cost innovative drugs?
  • Moving Drugs from Part B to Part D: Should Medicare Part D be expanded to cover more physician-administered drugs currently paid under Medicare Part B? Part B drugs are paid under a statutory formula of the average sales price, or ASP, plus 6 percent. Since ASP is based on manufacturer-set prices, net of discounts and rebates, and providers are guaranteed a margin, critics argue that the system encourages higher list prices.
  • Invigorating Part B Competitive Acquisition Program: What incentives would providers need to get out of the business of receiving a 6 percent markup on Part B drugs and turn the risk and reward over to their heretofore little-used competitive bidding program?
  • Fixing Global "Freeloading": It is generally acknowledged that the national health plans run by foreign countries pay less for prescription drugs than does Medicare or private U.S. plans. The administration argues that when Americans pay the higher, unregulated prices, they are subsidizing the lower foreign prices. Recognizing this fact, however, does not admit of an easy solution. The administration proposes to handle this through trade negotiations, and the president indicated that he has instructed the U.S. trade representative to make this a top priority. What carrots and sticks would the U.S. have to use to get foreign governments to pay more for prescription drugs or otherwise address this issue?
  • Site-Neutrality for Payment: Should states and other payers encourage drug administration in lower-cost settings (e.g., physician offices) by eliminating facility fees that pay institutions (e.g., hospitals) more for administration?

    • Assessment: This is a smorgasbord of ideas, most of which have rattled around health policy circles for many years. Most significant is perhaps the focus on addressing foreign "freeloading" through trade negotiation, which seems consistent with the administration's view that other countries don't pay their fair share for the benefits that the U.S. bestows, which in this case includes substantial public sector investment in research and development. Payment formula and private sector changes likely would require congressional action, as would eliminating coverage for physician-administered drugs under Part B

3. Reduce the List Prices Set by Manufacturers

The administration's primary immediate approach might be best characterized as subjecting drugmakers to "cost shaming" by making their prices and price increases more public. Longer term, and consistent with remarks in the president's speech about how the "middlemen" won't be so rich anymore, the blueprint asks genuinely provocative questions about whether the existing business model for drug delivery should be fundamentally changed. It does this by asking leading questions about whether the role of pharmacy benefit managers, or PBMs, should be curtailed, and raises similar questions about the scope of the 340b safety net hospital discount program and patient coinsurance discount cards.

What the Administration "May" Do

  • Direct-to-Consumer Ads: The FDA may evaluate whether to require that DTC drug advertisements include the list price of the drug.
  • Medicare/Medicaid Dashboard: CMS may create a dashboard of pricing information to advise consumers of drug prices and of price increases.
  • Follow the Lead of the States: Another step to encourage competition could be to follow the lead of a number of states and require drugmakers to publish or otherwise disclose price increases and a rationale.

    • Assessment: It is not clear that the FDA has the authority to require prices to be included in DTC ads, and such efforts might be met with First Amendment challenges as well. While many cost-shaming measures could be accomplished through administrative action, it also is not clear that such cost-shaming would lead drugmakers to implement more voluntary price reductions.

What the Administration Is Seeking Ideas About

  • Fiduciary Duty for PBMs: Should the business model for pharmacy benefit management in which PBMs receive their payment from drug manufacturers in the form of rebates and administrative fees that depend on the volume or value of products sold, be changed so that PBMs act as the fiduciary for their health plan members and presumably are no longer paid on this basis?
  • Reducing the Impact of Rebates: Would requiring a restriction or reduction in Part D rebates paid to PBMs result in lower list prices, and would that lead drug manufacturers to lower list prices in a way significant enough to advantage health plans and consumers?
  • Coinsurance Discount Cards: Should action be taken to eliminate or restrict the use of manufacturer-provided discount cards that help patients with copay and coinsurance, which critics argue incentivizes higher list prices?
  • 340b Discount Program: Does the 340b program of requiring manufacturers to give drug discounts to safety net hospitals lead to higher list prices because drug manufacturers must cross-subsidize, and if so should the scope of the program be reduced?

    • Assessment: Changes in these areas would fundamentally remake the existing prescription drug insurance marketplace, albeit in unpredictable ways, and Congressional action would certainly be required.

4. Ease Out-of-Pocket Costs

What the Administration "May" Do

  • Prohibiting "Gag Clauses": Here the administration proposes to piggyback on initiatives already enacted in several states and require that Part D plans prohibit their PBMs from restricting pharmacists from discussing lower cost alternatives with patients.
  • More Consumer Information: Require Part D plans to provide their members with additional information about drug prices and lower cost alternatives in their explanations of benefits.
  • Ease OTC Approvals: While not mentioned in the blueprint, the president suggested in his speech that another approach could be to move more drugs to over-the-counter status, which might in some cases lead to lower cost.

    • Assessment: All of these modest informational efforts likely could be implemented through administrative action, and would rely on consumers taking more ownership of their own health care costs.

What the Administration Is Seeking Ideas About

  • More Consumer Information Redux: The same elements listed immediately above are also detailed as items on which the administration seeks more information on impact.

    • Assessment: That these ideas show up as current steps and as information-seeking suggests a paucity of ideas on how to ease out-of-pocket costs.

Footnote

1. https://www.hhs.gov/sites/default/files/AmericanPatientsFirst.pdf

This article was published by Law360 on May 17, 2018.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions